For purposes of this policy, predominantly non-upper lobe predominance of emphysema is defined to exclude disease on CT that is judged by the radiologist as affecting primarily the upper lobes of the lung, and to include disease that is judged to be predominantly lower lobe, diffuse, or predomi...
DCD lungs preserved with portable EVLP had a significantly shorter cold ischemic time (161 ± 44 versus 234 ± 60 mins, p = 0.045), lower grade of PGD at 72 hours after LTX (0.4 ± 0.5 versus 2.1 ± 0.7, p = 0.003), similar mechanical ventilation time (55 ± 44 versus 103 ± 97 ...
Notably, the cumulative incidence of SPLC increased over time in breast cancer survivors even though the 10-year incidence level was relatively low, at 0.47%. While this incidence rate is comparable to or higher than the one (0.29%) based on a previous European study,5 it is still lower th...
www.nature.com/scientificreports OPEN received: 10 August 2015 accepted: 18 November 2015 Published: 18 December 2015 Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients Bao-Tian Huang1,*, Zhu Lin1,*, Pei-Xian Lin2, Jia-...
Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic...
Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based on expression of ASCL1, NEUROD1, POU2F3, or YAP1. Here, we use mouse and human models with a time-series single-cell...
left; the lower border of the bronchus intermedius on the right Nodes lying adjacent to the wall of the esophagus and to the right or left of the midline, excluding subcarinal nodes Upper border: the upper border of the lower lobe bronchus on the left; the lower border of the bronchus...
non-small-cell lung cancer;immune checkpoint inhibitors;immunotherapy;anti-PD1/PD-L1;lung resection;safety Graphical Abstract 1. Introduction In the last ten years, the development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape of non-small-cell lung cancers (NSCLC)...
Keywords: non-small cell lung cancer; chemoradiotherapy; toxicity; esophagitis; pneumonitis; pulmonary fibrosis; hematologic toxicity; cardiac toxicity 1. Introduction The second most common noncutaneous neoplasm in both men and women, lung cancer, will be diagnosed in an estimated 222,500 patients in...
An earlier study comparing the microbial communities sampled by multiple respiratory tract sites of healthy individuals, demonstrated that the bacterial population of the left lower lobar bronchus retrieved by EB was generally larger than the populations of the right middle lobe segmental bronchi, which...